BPG is committed to discovery and dissemination of knowledge
Articles in Press
4/13/2017 11:02:38 AM | Browse: 560 | Download: 719
Category |
Research & Experimental Medicine |
Manuscript Type |
Basic Study |
Article Title |
Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Latha Paka, David E Smith, Dawoon Jung, Siobhan McCormack, Ping Zhou, Bin Duan, Jing-Song Li, Jiaqi Shi, Yong-Jie Hao, Kai Jiang, Michael Yamin, Itzhak D Goldberg and Prakash Narayan |
Funding Agency and Grant Number |
|
Corresponding Author |
Latha Paka, PhD, Senior Research Scientist, Department of Research and Development, Angion Biomedica Corp., 51 Charles Lindbergh Blvd, Uniondale, NY 11553, United States. spaka@angion.com |
Key Words |
High fat diet; Liver; Steatosis; Fibrosis; KCa3.1 channel; Senicapoc; Inflammation |
Core Tip |
Given the large numbers of people with fatty livers and even relatively indolent steatosis can result in a significant population progressing to non-alcoholic steatohepatitis (NASH), NASH with fibrosis and cirrhosis. We report for the first time that a KCa3.1 channel inhibitor exerts an anti-steatotic effect in the setting of fatty liver disease which can be harnessed for the treatment of liver fibrosis. Second, we are the first to report that Senicapoc, a drug that has been through Phase Ⅲ clinical trials, can be repurposed for the treatment of fatty liver disease and potentially for the treatment of other lipid disorders. |
Citation |
Paka L, Smith DE, Jung D, McCormack S, Zhou P, Duan B, Li JS, Shi J, Hao YJ, Jiang K, Yamin M, Goldberg ID, Narayan P. Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease. World J Gastroenterol 2017; 23(23): 4181-4190 |
 |
Received |
|
2016-11-18 09:21 |
 |
Peer-Review Started |
|
2016-11-21 16:15 |
 |
To Make the First Decision |
|
2017-01-19 13:54 |
 |
Return for Revision |
|
2017-01-20 14:53 |
 |
Revised |
|
2017-02-04 05:48 |
 |
Second Decision |
|
2017-04-11 15:49 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2017-04-13 11:02 |
 |
Articles in Press |
|
2017-04-13 11:02 |
 |
Publication Fee Transferred |
|
2017-05-26 08:54 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2017-06-12 09:25 |
ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. |
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345